Hologic (HOLX) Q3 Earnings and Revenues Beat Estimates

Financial Performance - Hologic reported quarterly earnings of $1.08 per share, exceeding the Zacks Consensus Estimate of $1.05 per share, and showing a slight increase from $1.06 per share a year ago, resulting in an earnings surprise of +2.86% [1] - The company posted revenues of $1.02 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.68%, compared to revenues of $1.01 billion in the same quarter last year [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.09 on revenues of $1.04 billion, while for the current fiscal year, the estimate is $4.19 on revenues of $4.08 billion [7] - The trend of estimate revisions for Hologic was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - Hologic operates within the Zacks Medical - Instruments industry, which is currently ranked in the bottom 35% of over 250 Zacks industries, suggesting potential challenges for stock performance compared to higher-ranked industries [8] - The performance of Hologic's stock may be influenced by the overall outlook for the medical instruments industry, as empirical research indicates a strong correlation between near-term stock movements and earnings estimate revisions [5][8]